EUVIMEDEUVIMED entdecken
Fallbericht

Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial

Mark T J VAN Bussel, Nathalie Bravenboer, Huib VAN Essen, Petur Snaebjornsson, Natasha M Appelman-Dijkstra, Jan Hm Schellens, Frans L Opdam

Anticancer Research · 2025

DOI: 10.21873/anticanres.17677 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Anticancer Research, 2025. Verfasst von Mark T J VAN Bussel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands m.v.bussel@nki.nl. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsAgedHumansMaleCarbamatesCetuximabMutationProto-Oncogene MasProto-Oncogene Proteins B-rafSulfonamidesWnt ProteinsClinical Trials, Phase I as Topic

Stichwörter der Autor:innen

Bone fracturesCTXP1NPWNT inhibitioncetuximabencorafenibhypercalcemiametastatic colorectal cancerporcupine inhibitor

Substanzen

BRAF protein, humanCarbamatesCetuximabencorafenibMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins B-rafSulfonamidesWnt Proteins

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands m.v.bussel@nki.nl.
  • Division Endocrinology, Department of Medicine, Center for Bone Quality, Leiden University Medical Center, Leiden, the Netherlands.
  • Amsterdam University Medical Centers, Department of Laboratory Science, and Amsterdam Movement Sciences Institute, Amsterdam, the Netherlands.
  • Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.
  • Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Zitieren

APA

VAN Bussel, M. T. J., Bravenboer, N., Essen, H. V., Snaebjornsson, P., Appelman-Dijkstra, N. M., Schellens, J. H., & Opdam, F. L. (2025). Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial. Anticancer Research. https://doi.org/10.21873/anticanres.17677

Vancouver

VAN Bussel MTJ, Bravenboer N, Essen HV, Snaebjornsson P, Appelman-Dijkstra NM, Schellens JH, et al. Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial. Anticancer Research. 2025. doi:10.21873/anticanres.17677

BibTeX
@article{VANBussel2025,
  author = {VAN Bussel, Mark T J and Bravenboer, Nathalie and Essen, Huib VAN and Snaebjornsson, Petur and Appelman-Dijkstra, Natasha M and Schellens, Jan Hm and Opdam, Frans L},
  title = {Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17677}
}
Kostenlos starten →